Novel antidiabetic agents

Bibliography

• TAYLOR SI, ACCILI D, IMAI Y: Insulin resistance orinsulin deficiency. Which is the primary cause of NIDDM? Diabetes (1994) 43:735–740.
   Google Scholar
• WILLIAMS G: Management of non-insulin-dependentdiabetes mellitus. Lancet (1994) 343:95–100.
   PubMed Web of Science ®Google Scholar
• SHINKAI H: Recent developments in oral hypogly-cemic agents. Drug discover)/ today (1994) 4:283–288.
   Google Scholar
• PORTE D JR., SCHWARTZ MW: Diabetes complications:why is glucose potentially toxic? Science (1996) 272:699–700.
   PubMedGoogle Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854–865.
   PubMed Web of Science ®Google Scholar
• SOHDA T, MIZUNO K, IMAMIYA E et al: Studies on antidiabetic agents. II. Synthesis of 544-(1-methyl-cyclohexylmethoxy)benzylithiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem. Pharm. (1982) 30:3580–3600.
   Google Scholar
• FUJITA T, SUGIYAMA Y, TAKETOMI S et al.: Reduction of insulin resistance in obese and diabetic animals by 5- [4-(1-methylcyclohexylmethoxy)benzyl]thiazolidin e-2,4-dione (ADD-3878, U63,287, ciglitazone), a new antidiabetic agent. Diabetes (1983) 32:804–810.
   PubMed Web of Science ®Google Scholar
• HULIN B, MCCARTHY PA, GIBBS EM: The glitazone family of antidiabetic agents. Curr. Pharm. Des. (1996) 2:85–102.
   Web of Science ®Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA, WILKISON WO, WILLSON TM, KLIEWER SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxi-some proliferator-activated receptor y (PPAR y). J. Biol. Chem. (1995) 270:12953–12956.
   PubMed Web of Science ®Google Scholar
• WILLSON TM, COBB JE, COWAN DJ et al.: The structure-activity relationship between peroxisome proliferator-activated receptor y agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. (1996) 39:665–668.
   PubMed Web of Science ®Google Scholar
• SPIEGELMAN BM: PPAR-y: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 47:507–514.
   PubMed Web of Science ®Google Scholar
• SHINKAI H: The isoxazolidine-3,5-dione hypoglycemic agent JTT-501 and other nonthiazolidinedione insulin sensitizers. Drugs Fut. (1999) 24:893–898.
   Google Scholar
• YOSHIOKA T, FUJITA T, KANAI T et al: Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem. (1989) 32:421–428.
   Google Scholar
• OAKES ND, KENNEDY CY, JENKINS AB et al: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in rat. Diabetes (1994) 43:1203–1210.
   PubMed Web of Science ®Google Scholar
• SOHDA T, MOMOSE Y, MEGURO K, KAWAMATSU Y, SUGIYAMA Y, IKEDA H: Studies on antidiabetic agents. Synthesis and hypoglycemic acitvity of 5- [4- (pyridylalkoxy)benzy1]-2,4-thiazolidinediones. Arzneim-Forsch/Drug Res. (1990) 40:37–42.
   Google Scholar
• IWAMOTO Y, KOSAKA K, KUZUYA T, AKANUMA Y, SHIGETA Y, KANEKO T: Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care (1996) 19:151–156.
   PubMed Web of Science ®Google Scholar
• SOHDA T, MIZUNO K, TAWADA H, SUGIYAMA Y, FUJITAT, KAWAMATSU Y: Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy) benzyl]thiazolidine-2,4-dione (AL-321) and related compounds. Chem. Pharm. Bull. (1982) 30:3563–3573.
   Google Scholar
• SHINKAI H, ONOGI S, TANAKA M et al.: Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. J. Med. Chem. (1998) 41:1927–1933.
   PubMed Web of Science ®Google Scholar
• SHIBATA T, MATSUI K, YONEMORI F, WAKITANI K: JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models. Br. J. Pharmacol (1998) 125:1744–1750.
   PubMedGoogle Scholar
• SHIBATA T, MATSUI K, NAGAO K, SHINKAI H, YONEMORI F, WAKITANI K: Pharmacological profiles of a novel antidiabetic agnet, JTT-501, an isoxazolidinedione derivative. Eur. J. Pharmacol. (1999) 364:211–219.
   PubMedGoogle Scholar
• HENKE BR, BLANCHARD SG, BRACKEEN MF et al.: N-(2-Benzoylpheny1)-t-tyrosine PPARy agonists. 1. Discovery of a novel series of potent antihypergly-cemic and antihyperlipidemic agnets. J. Med. Chem. (1998) 41:5020–5036.
   Google Scholar
• COLLINS JL, BLANCHARD SG, BOSWELL GE et al.:N-(2-Benzoylpheny1)-t-tyrosine PPARy agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem. (1998) 41:5037–5054.
   Google Scholar
• COBB JE, BLANCHARD SG, BOSWELL GE et al.: N-(2-Benzoylpheny1)-t-tyrosine PPARy agonists. 2. Structure-activity relationship and optimization of the N-aryl substituent. J. Med. Chem. (1998) 41:5055–5069.
   Google Scholar
• BUCKLE DR, CANTELLO BCC, CAWTHORNE MA et al.: Non thiazolidinedione antihyperglycaemic agents. 1: a-Heteroatom substituted 6-phenylpropanoic acids. Bioorg. Med. Chem. Lett. (1996) 6:2121–2126.
   Google Scholar
• HULIN B, NEWTON LS, LEWIS DM et al.: Hypoglycemic activity of a series of a-alkylthio and a-alkoxy carbox-ylic acids related to ciglitazone. J. Med. Chem. (1996) 39:3897–3907.
   PubMed Web of Science ®Google Scholar
• BUCKLE DR, CANTELLO BCC, CAWTHORNE MA et al.: Non thiazolidinedione antihyperglycaemic agents. 2: a-Carbon substituted 6-pheylpropanoic acids. Bioorg. Med. Chem. Lett. (1996) 6:2127–2130.
   Google Scholar
• MUKHERJEE R, DAVIES PJA, CROMBIE DL et al.: Sensitiza-tion of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (1997) 386:407–410.
   PubMed Web of Science ®Google Scholar
• SHINKAI H, NISHIKAWA M, SATO Y et al.: N-(Cyclohexyl-carbonyfi-u-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2. J. Med. Chem. (1989) 32:1436–1441.
   Google Scholar
• SHINKAI H, SATO Y: Hypoglycaemic action of phenylalanine derivatives. In: New antidiabetic drugs. BAILEY CJ, FLATT PR (Eds.), Smith-Gordon, London, UK (1990)249–254.
   Google Scholar
• IKENOUE T, AKIYOSHI M, FUJITANI S et al.: Hypogly-caemic and insulinotropic effects of a novel oral antidiabetic agent,(-) -N-(trans-4-isopropyl cyclohex-anecarbony1)-D-phenylalanine (A-4166). Br. J. Pharmacol. (1997) 120:137–145.
   PubMed Web of Science ®Google Scholar
• GEISEN K, HUBNER M, HITZEL V et al.: Acylaminoalkyl-substituierte benzoe- und phenylalkansäuren mit blutglukose-senkender wirkung. Arzneim-Forsch/Drug Res. (1978) 28:1081–1083.
   PubMedGoogle Scholar
• VERSPOHL EJ, AMMON HPT, MARK M: Evidence for more than one binding site for sulfonylureas in insulin-secreting cells. J. Pharm. Pharmacol. (1990) 42:230–235.
   PubMedGoogle Scholar
• WOLFFENBUTTEL BHR, NIJST L, SELS JPJE et al.: Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur.j Clin. Pharmacol (1993) 45:113–116.
   PubMed Web of Science ®Google Scholar
• GRONADA J, DISSING S, KOFOD H, FROKJAER-JENSEN J: Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in 6 TC3 cells and rat pancreatic beta cells. Diabetologia (1995) 38:1025–1032.
   PubMedGoogle Scholar
• WANG F: Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas. Formulary (1998) 33:409–423.
   Google Scholar
• FUHLENDORFF J, RORSMAN P, KOFOD H et al.: Stimula-tion of insulin release by repaglinide and glibencla-mide involves both common and distinct processes. Diabetes (1998) 47:345–351.
   PubMed Web of Science ®Google Scholar
• DEACON CF, HUGHES TE, HOLST JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes (1998) 47:764–769.
   PubMed Web of Science ®Google Scholar
• COUTTS SJ, KELLY TA, SNOW RJ et al.: Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of X..-boro Pro dipeptides. J. Med. Chem. (1996) 39:2087–2094.
   Google Scholar
• HUGHES TE, BALKAN B, VILLHAUER EB: NVP-DPP728, a novel, orally active dipeptidyl peptidase IV (DPP-IV) inhibitor, prevents glucagon-like peptide-1 (GLP-1) inactivation in rats. Diabetes (1999) suppl. 1:A21.
   Google Scholar
• HOOVER DJ, LEFKOWITZ-SNOW S, BURGESS-HENRY JL et Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J. Med. Chem. (1998) 41:2934–2938.
   PubMed Web of Science ®Google Scholar
• SHINKAI H, OZEKI H, MOTOMURA T et al.:4- trans-4-Methylcyclohexyl)-4-oxobutyric acid (JTT-608). A new class of antidiabetic agent. J. Med. Chem. (1998) 41:5420–5428.
   Google Scholar